| 1 |
Xia C，Dong X，Li H，et al．Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]．Chin Med J (Engl)，2022，135（5）：584-590．
|
| 2 |
Goldstraw P，Chansky K，Crowley J，et al．The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer[J]．J Thorac Oncol，2016，11（1）：39-51．
|
| 3 |
Zhong WZ，Yan HH，Chen KN，et al．Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial[J]．Signal Transduct Target Ther，2023，8（1）：76．
|
| 4 |
Forde PM，Chaft JE，Smith KN，et al．Neoadjuvant PD-1 Blockade in Resectable Lung Cancer[J]．N Engl J Med，2018，378（21）：1976-1986．
|
| 5 |
Provencio M，Nadal E，Insa A，et al．Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial[J]．Lancet Oncol，2020，21（11）：1413-1422．
|
| 6 |
Shen D，Wang J，Wu J，et al．Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB-IIIB resectable lung squamous cell carcinoma[J]．J Thorac Dis，2021，13（3）：1760-1768．
|
| 7 |
Liang H，Yang C，Gonzalez-Rivas D，et al．Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer[J]．Transl Lung Cancer Res，2021，10（1）：143-155．
|
| 8 |
Liu W，Zhang T，Zhang Q，et al．A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer[J]．BMC Pulm Med，2022，22（1）：490．
|
| 9 |
Duan J，Tan F，Bi N，et al．Expert consensus on perioperative treatment for non-small cell lung cancer[J]．Transl Lung Cancer Res，2022，11（7）：1247-1267．
|
| 10 |
Szeto CH，Shalata W，Yakobson A，et al．Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer，Past，Present，and Future[J]．J Clin Med，2021，10（23）：5614．
|
| 11 |
Xu Y，Lyu X，Qin Y，et al．Multi-organs perioperative immune-related adverse events and postoperative bronchial anastomotic fistula in a patient receiving neoadjuvant immunotherapy with NSCLC[J]．Thorac Cancer，2022，13（16）：2340-2345．
|
| 12 |
倪军，黄淼，张力，等．非小细胞肺癌围手术期免疫治疗相关不良反应管理的临床诊疗建议[J]．中国肺癌杂志，2021，24（3）：141-160．
|
| 13 |
白向豆，洪子强，崔百强，等．胸腔镜肺叶切除术中肺动、静脉切断顺序对非小细胞肺癌患者手术疗效与安全性影响的系统评价[J]．肿瘤防治研究，2023，50（1）：69-74．
|
| 14 |
Li F，Jiang G，Chen Y，et al．Curative Effects of Different Sequences of Vessel Interruption During the Completely Thoracoscopic Lobectomy on Early Stage Non-Small Cell Lung Cancer[J]．Ann Thorac Cardiovasc Surg，2015，21（6）：536-543．
|
| 15 |
Wei S，Guo C，He J，et al．Effect of Vein-First vs Artery-First Surgical Technique on Circulating Tumor Cells and Survival in Patients With Non-Small Cell Lung Cancer：A Randomized Clinical Trial and Registry-Based Propensity Score Matching Analysis[J]．JAMA Surg，2019，154（7）：e190972．
|
| 16 |
Berry MF．Pulmonary Artery Bleeding During Video-Assisted Thoracoscopic Surgery：Intraoperative Bleeding and Control[J]．Thorac Surg Clin，2015，25（3）：239-247．
|